Safety of PCI-32765 in Chronic Lymphocytic Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

December 31, 2012

Study Completion Date

February 28, 2013

Conditions
B-cell Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Interventions
DRUG

PCI-32765

420 mg daily or 840 mg daily

Trial Locations (10)

10065

New York Presbyterian Hosptial Cornell Med Center, New York

37203

Sarah Cannon, Nashville

43210

The Ohio State University, Columbus

75702

Texas Oncology - Tyler, Tyler

77030

MD Anderson Cancer Center, Houston

94305

Stanford University School of Medicine, Stanford

97477

Willamette Valley Cancer Institute and Research Center, Springfield

98686

Northwest Cancer Specialists, P.C., Vancouver

98902

Yakima Valley Memorial, Yakima

05405

University of Vermont and Fletcher Allen Health Care, Burlington

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pharmacyclics LLC.

INDUSTRY

NCT01105247 - Safety of PCI-32765 in Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter